Skip to main content
Home
Latest news
Browse topics
Lupus
Rheumatoid arthritis
Spondyloarthropathies
COVID-19
Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022
EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Log in

17-06-2017 | EULAR 2017 | Video

EULAR 2017 highlights: Roy Fleischmann

This activity is financially supported by Novartis Pharma AG

Related content

22-06-2017 | Rheumatoid arthritis | News

Support for adding tofacitinib to methotrexate in patients with RA

04-08-2017 | Rheumatoid arthritis | Feature | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?
How FDA alert about pulmonary embolism will affect rheumatoid arthritis treatment decisions

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Methotrexate withdrawal feasible with tofacitinib in patients with RA

Image Credits